These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 29931042)

  • 1. HUME: large-scale detection of causal genetic factors of adverse drug reactions.
    Mansouri M; Yuan B; Ross CJD; Carleton BC; Ester M
    Bioinformatics; 2018 Dec; 34(24):4274-4283. PubMed ID: 29931042
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Large-scale identification of adverse drug reaction-related proteins through a random walk model.
    Chen X; Shi H; Yang F; Yang L; Lv Y; Wang S; Dai E; Sun D; Jiang W
    Sci Rep; 2016 Nov; 6():36325. PubMed ID: 27805066
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Biomarkers of adverse drug reactions.
    Carr DF; Pirmohamed M
    Exp Biol Med (Maywood); 2018 Feb; 243(3):291-299. PubMed ID: 28950720
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rapid Assessment of Adverse Drug Reactions by Statistical Solution of Gene Association Network.
    Xiang YP; Liu K; Cheng XY; Cheng C; Gong F; Pan JB; Ji ZL
    IEEE/ACM Trans Comput Biol Bioinform; 2015; 12(4):844-50. PubMed ID: 26357325
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identifying the common genetic networks of ADR (adverse drug reaction) clusters and developing an ADR classification model.
    Hwang Y; Oh M; Jang G; Lee T; Park C; Ahn J; Yoon Y
    Mol Biosyst; 2017 Aug; 13(9):1788-1796. PubMed ID: 28702565
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Canadian Pharmacogenomics Network for Drug Safety: a model for safety pharmacology.
    Ross CJ; Visscher H; Sistonen J; Brunham LR; Pussegoda K; Loo TT; Rieder MJ; Koren G; Carleton BC; Hayden MR;
    Thyroid; 2010 Jul; 20(7):681-7. PubMed ID: 20578893
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Predicting serious rare adverse reactions of novel chemicals.
    Poleksic A; Xie L
    Bioinformatics; 2018 Aug; 34(16):2835-2842. PubMed ID: 29617731
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Frequency, types, severity, preventability and costs of Adverse Drug Reactions at a tertiary care hospital.
    Geer MI; Koul PA; Tanki SA; Shah MY
    J Pharmacol Toxicol Methods; 2016; 81():323-34. PubMed ID: 27109493
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adverse Drug Reactions to Anti-TB Drugs: Pharmacogenomics Perspective for Identification of Host Genetic Markers.
    Sahu RK; Singh K; Subodh S
    Curr Drug Metab; 2015; 16(7):538-52. PubMed ID: 26264201
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Data-driven prediction of adverse drug reactions induced by drug-drug interactions.
    Liu R; AbdulHameed MDM; Kumar K; Yu X; Wallqvist A; Reifman J
    BMC Pharmacol Toxicol; 2017 Jun; 18(1):44. PubMed ID: 28595649
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical association between pharmacogenomics and adverse drug reactions.
    Zhou ZW; Chen XW; Sneed KB; Yang YX; Zhang X; He ZX; Chow K; Yang T; Duan W; Zhou SF
    Drugs; 2015 Apr; 75(6):589-631. PubMed ID: 25895462
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A potential causal association mining algorithm for screening adverse drug reactions in postmarketing surveillance.
    Ji Y; Ying H; Dews P; Mansour A; Tran J; Miller RE; Massanari RM
    IEEE Trans Inf Technol Biomed; 2011 May; 15(3):428-37. PubMed ID: 21435986
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of patient reporting of adverse drug reactions to the UK 'Yellow Card Scheme': literature review, descriptive and qualitative analyses, and questionnaire surveys.
    Avery AJ; Anderson C; Bond CM; Fortnum H; Gifford A; Hannaford PC; Hazell L; Krska J; Lee AJ; McLernon DJ; Murphy E; Shakir S; Watson MC
    Health Technol Assess; 2011 May; 15(20):1-234, iii-iv. PubMed ID: 21545758
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Supervised signal detection for adverse drug reactions in medication dispensing data.
    Hoang T; Liu J; Roughead E; Pratt N; Li J
    Comput Methods Programs Biomed; 2018 Jul; 161():25-38. PubMed ID: 29852965
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Direct costs and clinical aspects of adverse drug reactions in patients admitted to a level 3 hospital internal medicine ward].
    Tribiño G; Maldonado C; Segura O; Díaz J
    Biomedica; 2006 Mar; 26(1):31-41. PubMed ID: 16929901
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adverse drug reactions in neonates: a prospective study.
    Belén Rivas A; Arruza L; Pacheco E; Portoles A; Diz J; Vargas E
    Arch Dis Child; 2016 Apr; 101(4):371-6. PubMed ID: 26819267
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fast Screening Technology for Drug Emergency Management: Predicting Suspicious SNPs for ADR with Information Theory-based Models.
    Liang Z; Liu J; Huang JX; Zeng X
    Comb Chem High Throughput Screen; 2018; 21(2):93-99. PubMed ID: 29336255
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Detecting adverse drug reactions on paediatric wards: intensified surveillance versus computerised screening of laboratory values.
    Haffner S; von Laue N; Wirth S; Thürmann PA
    Drug Saf; 2005; 28(5):453-64. PubMed ID: 15853446
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Systematic analysis of the associations between adverse drug reactions and pathways.
    Chen X; Wang Y; Wang P; Lian B; Li C; Wang J; Li X; Jiang W
    Biomed Res Int; 2015; 2015():670949. PubMed ID: 26495310
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adverse drug reactions experience in a teaching hospital in Jordan.
    Alsbou M; Alzubiedi S; Alzobi H; Samhadanah NA; Alsaraireh Y; Alrawashdeh O; Aqel A; Al-Salem K
    Int J Clin Pharm; 2015 Dec; 37(6):1188-93. PubMed ID: 26286340
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.